Wells Fargo
MAZE

Wells Fargo’s Maze Therapeutics MAZE Stock Holding History

Wells Fargo’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$310K Sell
10,369
-13,639
-57% -$602K ﹤0.01% 4428
2025
Q4 		$995K Buy
24,008
+9,229
+62% +$317K ﹤0.01% 3976
2025
Q3 		$383K Buy
14,779
+9,164
+163% +$155K ﹤0.01% 4491
2025
Q2 		$68.9K Buy
5,615
+922
+20% +$9.59K ﹤0.01% 5391
2025
Q1 		$51.7K Buy
+4,693
New +$56.5K ﹤0.01% 5384

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wells Fargo's MAZE Position: Q1 2026 in Review

Wells Fargo reduced its Maze Therapeutics (MAZE) stake by 57% in Q1 2026, selling an estimated $602K and leaving 10,369 shares worth $310K. The position accounts for ﹤0.01% of the portfolio, ranked #4428.

Wells Fargo first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. The position peaked at $995K in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Wells Fargo held 10,369 shares of Maze Therapeutics worth $310K as of Q1 2026.
  • Wells Fargo sold 13,639 Maze Therapeutics shares in Q1 2026, an estimated $602K.
  • Maze Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4428 holding.
  • Wells Fargo first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Wells Fargo's Maze Therapeutics position peaked at $995K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.